Opinion
Video
IL-13–Targeting Agents in Atopic dermatitis
Panelists discuss the differences between the 3 FDA-approved IL-13–targeting agents for atopic dermatitis (AD)—dupilumab, tralokinumab, and lebrikizumab—and how these differences in their mechanisms of action might impact their effectiveness in targeting the disease and addressing various patient needs.
Video content above is prompted by the following:
- There are 3 IL-13–targeting agents that are FDA-approved for treatment of AD (dupilumab, tralokinumab, and lebrikizumab).
- How do they differ from each other?
- How might these differences impact how these drugs target the disease?
Related Videos
Related Content
